OAC Newsroom

Welcome, Madrigal Pharmaceuticals, Inc., to the Obesity Action Coalition’s Chairman’s Council!
in OAC Blog, OAC Newsroom on June 12, 2024

The Obesity Action Coalition (OAC) is pleased to share that Madrigal Pharmaceuticals, Inc. has joined OAC’s Chairman’s Council at the Bronze level! Thank you for committing to supporting and championing the OAC’s mission. About Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company pursuing novel therapeutics for nonalcoholic steatohepatitis (NASH), a liver disease with
Read Article

Obesity Action Coalition and STOP Obesity Alliance Collaborate on new Medicaid Obesity Treatment Coverage Research
in 2024 New Releases, OAC Blog, OAC Newsroom on June 3, 2024

Tampa, Fla., June 3, 2024—The Obesity Action Coalition (OAC) and the STOP Obesity Alliance are proud to announce the release of the “Medicaid Obesity Treatment Coverage Study.” This study is the first to analyze and investigate levels of state Medicaid coverage for obesity treatment options, beyond whether a benefit was covered or not. Healthcare plans
Read Article

50+ Patient & Provider Groups Urge the Biden Administration to Provide Comprehensive Care for Obesity
in 2024 New Releases, OAC Blog, OAC Newsroom on May 28, 2024

Tampa, FL, May 28, 2024 – This week, the Obesity Action Coalition (OAC), along with 57 other organizations, delivered a letter to the Biden Administration to call on the Department of Health and Human Services (HHS) and the Centers for Medicare and Medicaid Services (CMS) to provide access to comprehensive obesity care. The letter to
Read Article

Welcome, Boston Scientific, to the Obesity Action Coalition’s Chairman’s Council
in OAC Blog, OAC Newsroom on May 15, 2024

The Obesity Action Coalition (OAC) is pleased to share that Boston Scientific has joined OAC’s Chairman’s Council at the Silver level! Thank you for committing to support and champion the OAC’s mission. About Boston Scientific As a global medical technology leader for more than 40 years, Boston Scientific transforms lives through innovative medical technologies that improve the health
Read Article

Welcome, Biohaven Pharmaceuticals, to the Obesity Action Coalition’s Chairman’s Council
in OAC Blog, OAC Newsroom on May 13, 2024

The Obesity Action Coalition (OAC) is pleased to share that Biohaven Pharmaceuticals has joined OAC’s Chairman’s Council at the Bronze level! Thank you for committing to support and champion the OAC’s mission. About Biohaven Pharmaceuticals Biohaven is a biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including
Read Article

Obesity Action Coalition Urges CMS to Expand Coverage to Obesity Medications
in OAC Blog, OAC Newsroom on April 24, 2024

The Obesity Action Coalition, the Partnership to Advance Cardiovascular Health and more than 40 healthcare and advocacy organizations are urging the Centers for Medicare & Medicaid Services (CMS) to expand coverage and access to semaglutide for the treatment of obesity. We applaud CMS’s recent decision to cover obesity medications for patients with existing, high-risk cardiovascular
Read Article

Obesity Action Coalition (OAC) Calls for Minnesota Baseball Team St. Paul Saints to Change Offensive ‘Ozempig’ Mascot Name
in 2024 New Releases, News Releases, OAC Blog on April 1, 2024

Tampa, Fla. – The Obesity Action Coalition (OAC) condemns Minnesota minor league baseball team St. Paul Saints for naming their mascot ‘Ozempig’ and calls for an immediate change. The name mocks Ozempic, a medication primarily indicated for the treatment of diabetes but sometimes used off-label for the treatment of obesity. Diabetes and obesity affect millions
Read Article

Obesity Action Coalition (OAC) Releases Statement on Food and Drug Administration’s (FDA) Update to Wegovy® Label
in OAC Blog, OAC Newsroom on

The anti-obesity medication Wegovy® has been approved by the US Food and Drug Administration (FDA) for cardiovascular risk reduction in people with overweight or obesity and an established cardiovascular disease. The approval is based on the SELECT cardiovascular outcomes trial, which demonstrated that Wegovy® statistically significantly reduced the risk of major adverse cardiovascular events. Obesity
Read Article

Obesity Care Week 2024: 10 Years of Changing the Way We Care About Obesity
in 2024 New Releases, Events, OAC Blog, OAC Newsroom on March 4, 2024

  Tampa, Fla. – Today, Monday, March 4, marks the beginning of the 10th annual Obesity Care Week, a five-day public awareness campaign aiming to change the way we care by creating a society that understands, respects and accepts the complexities of the disease of obesity and prioritizes accessible, science-based treatment. With more than 130
Read Article

Obesity Action Coalition (OAC) Mobilizes Advocates on Capitol Hill to Mark the Start of Obesity Care Week 2024
in News Releases, OAC Blog, OAC Newsroom on March 1, 2024

WASHINGTON, DC — To kick off Obesity Care Week 2024, more than 60 advocates with the Obesity Action Coalition (OAC) will gather on Capitol Hill to meet with more than 70 legislators to express the importance of expanding access to obesity care by urging legislators to co-sponsor the Treat and Reduce Obesity Act (TROA). Obesity
Read Article

Found, the Obesity Medicine Association and the Obesity Action Coalition Take Steps to Close the Gap in Obesity Care With Launch of Obesity Medicine Scholarship
in OAC Blog, OAC Newsroom on February 16, 2024

More than 100 million adults in America are living with obesity, yet only 1% of providers are trained in obesity medicine, leaving many patients to turn to non-expert sources for medical information and prescriptions The Obesity Medicine Scholarship program, funded by Found, bridges the gap in care and encourages physicians to become American Board of
Read Article